Related references
Note: Only part of the references are listed.Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex
Amanda J. Sales et al.
MOLECULAR NEUROBIOLOGY (2019)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain
Mariana C. Diana et al.
CNS NEUROSCIENCE & THERAPEUTICS (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Fernanda F. Peres et al.
FRONTIERS IN PHARMACOLOGY (2018)
Impaired contextual fear-conditioning in MAM rodent model of schizophrenia
Kathryn M. Gill et al.
SCHIZOPHRENIA RESEARCH (2018)
Associations of attention-deficit/hyperactivity and other childhood disorders with psychotic experiences and disorders in adolescence
Timo Hennig et al.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY (2017)
How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review
Bettina Lange et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
Ashleigh L. Osborne et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Fear memory in a neurodevelopmental model of schizophrenia based on the postnatal blockade of NMDA receptors
Joachim Latusz et al.
PHARMACOLOGICAL REPORTS (2017)
Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
Marco Aurelio Mori et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders
Alline C. Campos et al.
FRONTIERS IN PHARMACOLOGY (2017)
Prediction of conversion to psychosis: review and future directions
Dylan G. Gee et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2017)
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
Kerstin Iffland et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
Andreza B. Sonego et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action
Mauricio dos-Santos-Pereira et al.
NEUROBIOLOGY OF DISEASE (2016)
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Raquel Linge et al.
NEUROPHARMACOLOGY (2016)
Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder
M. Lambert et al.
PHARMACOPSYCHIATRY (2016)
Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
F. F. Peres et al.
SCHIZOPHRENIA RESEARCH (2016)
Peripubertal exposure to environmental enrichment prevents schizophrenia-like behaviors in the SHR strain animal model
Camila Mauricio Santos et al.
SCHIZOPHRENIA RESEARCH (2016)
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
Fernanda F. Peres et al.
FRONTIERS IN PHARMACOLOGY (2016)
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Cathrin Rohleder et al.
FRONTIERS IN PHARMACOLOGY (2016)
Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Andrew C. McCreary et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
CANNABIDIOL INCREASES SURVIVAL AND PROMOTES RESCUE OF COGNITIVE FUNCTION IN A MURINE MODEL OF CEREBRAL MALARIA
A. C. Campos et al.
NEUROSCIENCE (2015)
Molecular Targets of Cannabidiol in Neurological Disorders
Clementino Ibeas Bih et al.
NEUROTHERAPEUTICS (2015)
Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)
Luiza Reali Nazario et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2015)
Cannabis use, gender and age of onset of schizophrenia: Data from the AESOP study
Kim Donoghue et al.
PSYCHIATRY RESEARCH (2014)
Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain
Valeria Almeida et al.
SCHIZOPHRENIA RESEARCH (2014)
N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice
Ana P. Herrmann et al.
SCHIZOPHRENIA RESEARCH (2014)
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
Raquel Levin et al.
FRONTIERS IN PHARMACOLOGY (2014)
Prediction and prevention of the first psychotic episode: new directions and opportunities
Sara Piras et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2014)
The contextual brain: implications for fear conditioning, extinction and psychopathology
Stephen Maren et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors
M. Ruth Pazos et al.
NEUROPHARMACOLOGY (2013)
Olanzapine Treatment of Adolescent Rats Causes Enduring Specific Memory Impairments and Alters Cortical Development and Function
Jean A. Milstein et al.
PLOS ONE (2013)
Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
Felipe V. Gomes et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
Valeria Almeida et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
The Psychosis High-Risk State A Comprehensive State-of-the-Art Review
Paolo Fusar-Poli et al.
JAMA PSYCHIATRY (2013)
How to calculate sample size in animal studies?
Jaykaran Charan et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2013)
Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia
Raquel Levin et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis
Tatiana Barichello et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
Alline Cristina Campos et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2012)
To poly(I:C) or not to poly(I:C): Advancing preclinical schizophrenia research through the use of prenatal immune activation models
Urs Meyer et al.
NEUROPHARMACOLOGY (2012)
Negative symptoms in individuals at clinical high risk of psychosis
Danijela Piskulic et al.
PSYCHIATRY RESEARCH (2012)
Anxiogenic-like effects of chronic cannabidiol administration in rats
Maha M. ElBatsh et al.
PSYCHOPHARMACOLOGY (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
The Neurodevelopmental Hypothesis of Schizophrenia Convergent Clues from Epidemiology and Neuropathology
Michael Piper et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2012)
Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala
Gislaine Z. Reus et al.
ACTA NEUROPSYCHIATRICA (2011)
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats
Mariana Bendlin Calzavara et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine
Raquel Levin et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Risperidone Administered During Asymptomatic Period of Adolescence Prevents the Emergence of Brain Structural Pathology and Behavioral Abnormalities in an Animal Model of Schizophrenia
Yael Piontkewitz et al.
SCHIZOPHRENIA BULLETIN (2011)
Comorbidity of schizophrenia and adult attention-deficit hyperactivity disorder
Rossen Donev et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2011)
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Mateus Machado Bergamaschi et al.
CURRENT DRUG SAFETY (2011)
Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture
Omar J. Cassol- et al.
BRAIN RESEARCH (2010)
Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation
I. Magen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
COGNITION IN TRANSMEMBRANE DOMAIN NEUREGULIN 1 MUTANT MICE
L. Duffy et al.
NEUROSCIENCE (2010)
Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
Abir T. El-Alfy et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2010)
Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia
Urs Meyer et al.
SCHIZOPHRENIA BULLETIN (2010)
Schizophrenia, Just the Facts 5. Treatment and prevention Past, present, and future
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2010)
Clozapine Administration in Adolescence Prevents Postpubertal Emergence of Brain Structural Pathology in an Animal Model of Schizophrenia
Yael Piontkewitz et al.
BIOLOGICAL PSYCHIATRY (2009)
ADOLESCENT AND ADULT MALE SPONTANEOUS HYPERACTIVE RATS (SHR) RESPOND DIFFERENTLY TO ACUTE AND CHRONIC METHYLPHENIDATE (RITALIN)
Elyssa Barron et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2009)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Neuroleptic Drugs Revert the Contextual Fear Conditioning Deficit Presented by Spontaneously Hypertensive Rats: A Potential Animal Model of Emotional Context Processing in Schizophrenia?
Mariana Bendlin Calzavara et al.
SCHIZOPHRENIA BULLETIN (2009)
Analysis of the chronic intake of and withdrawal from diazepam on emotional reactivity and sensory information processing in rats
J. De Ross et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Realistic expectations of prepulse inhibition in translational models for schizophrenia research
Neal R. Swerdlow et al.
PSYCHOPHARMACOLOGY (2008)
Uncontrollable voices and their relationship to gating deficits in schizophrenia
Veena Kumari et al.
SCHIZOPHRENIA RESEARCH (2008)
Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats
Jean-Charles Bizot et al.
PSYCHOPHARMACOLOGY (2007)
Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains
Pamela B. Yang et al.
BRAIN RESEARCH BULLETIN (2006)
Startle gating deficits in a large cohort of patients with schizophrenia - Relationship to medications, symptoms, neurocognition, and level of function
Neal R. Swerdlow et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder
Filip S. van den Bergh et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2006)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity
C Hamelink et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children
Ö Öner et al.
SCHIZOPHRENIA RESEARCH (2005)
Rodent models of attention-deficit/hyperactivity disorder
T Sagvolden et al.
BIOLOGICAL PSYCHIATRY (2005)
Differential locomotor responses in male rats from three strains to acute methylphenidate
B Amini et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2004)
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
A Giuffrida et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Prior juvenile diagnoses in adults with mental disorder - Developmental follow-back of a prospective-longitudinal cohort
J Kim-Cohen et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
A review of 25 years of the social interaction test
SE File et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Psychosis proneness and ADHD in young relatives of schizophrenia patients
MS Keshaven et al.
SCHIZOPHRENIA RESEARCH (2003)
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex:: role of 5-HT1A receptor agonism
J Ichikawa et al.
BRAIN RESEARCH (2002)
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
DL Braff et al.
PSYCHOPHARMACOLOGY (2001)
5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation:: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
J Ichikawa et al.
JOURNAL OF NEUROCHEMISTRY (2001)
To model a psychiatric disorder in animals: Schizophrenia as a reality test
BK Lipska et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Share Paper
